Multiple Myeloma Bone Marrow Mononuclear Cells
About:Multiple Myeloma Bone Marrow Mononuclear Cells - cryopreserved BMMCs isolated from clinically confirmed multiple myeloma donors. Diagnosis requires marrow clonal plasma cell infiltration of 10% or greater, making marrow the essential specimen for diagnosis, FISH cytogenetics, and monitoring. Ideal for plasma cell biology and marrow microenvironment research. Stratification by cytogenetic risk and treatment history.
About Multiple Myeloma Bone Marrow Mononuclear Cells
Multiple Myeloma Bone Marrow Mononuclear Cells for Plasma Cell Disorder Research
Multiple myeloma bone marrow mononuclear cells (BMMCs) are isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples come from consented donors under IRB-approved protocols, each clinically diagnosed with multiple myeloma — a malignancy of clonal plasma cells that reside and expand within the bone marrow.
Multiple Myeloma Biology and Why Bone Marrow
- Multiple myeloma diagnosis requires demonstration of clonal plasma cell infiltration of the bone marrow at 10% or greater (or a biopsy-proven plasmacytoma), making marrow aspirate the required diagnostic specimen.
- Fluorescence in situ hybridization (FISH) cytogenetics performed on marrow-derived plasma cells – detecting abnormalities such as t(4;14), t(14;16), and del(17p) – is the standard approach to risk stratification.
- The marrow microenvironment, including bone marrow stromal cells, osteoclasts, and immune cells, actively supports myeloma cell survival and drives the characteristic bone disease, making marrow material essential for microenvironment-focused research.
- Minimal residual disease assessment by next-generation flow cytometry or sequencing on marrow aspirate is increasingly used to guide treatment duration and predict outcomes.
- Novel immunotherapies, including BCMA-targeted CAR-T and bispecific antibodies, rely on marrow-derived plasma cells for target-expression and functional studies.
Donor Stratification Available
- Cytogenetic risk group, including t(4;14), t(14;16), and del(17p) status where documented
- Disease stage (R-ISS) and plasma cell percentage at collection
- Treatment history, including immunotherapy or stem cell transplant
- Light chain type and other biomarker status where documented
- Age band and sex assigned at birth
- Matched healthy bone marrow controls available
Product Features
- Isolated from clinically confirmed multiple myeloma donor bone marrow aspirate
- Density-gradient purified and cryopreserved
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom cell quantities available
De-identified Donor Data
- Multiple myeloma diagnosis confirmation and cytogenetic risk group where documented
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Treatment history and disease stage where documented
- Additional myeloma-specific metadata available on request
Applications
- FISH cytogenetics and risk-stratification studies
- Marrow microenvironment and bone disease mechanism research
- BCMA-targeted CAR-T and bispecific antibody target-expression studies
- Minimal residual disease assay development
- Plasma cell biology and clonal evolution research
Other Specimen Types
For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection, and our multiple myeloma PBMCs for peripheral blood-based studies.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Multiple myeloma BMMCs are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please contact our team to confirm compatibility with your country’s regulations.
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Bone Marrow Mononuclear Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Need a custom Bone Marrow Mononuclear Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.